BRPI0923448A2 - vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina. - Google Patents

vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.

Info

Publication number
BRPI0923448A2
BRPI0923448A2 BRPI0923448A BRPI0923448A BRPI0923448A2 BR PI0923448 A2 BRPI0923448 A2 BR PI0923448A2 BR PI0923448 A BRPI0923448 A BR PI0923448A BR PI0923448 A BRPI0923448 A BR PI0923448A BR PI0923448 A2 BRPI0923448 A2 BR PI0923448A2
Authority
BR
Brazil
Prior art keywords
influenza virus
vaccine
individual
rearranged
eliciting
Prior art date
Application number
BRPI0923448A
Other languages
English (en)
Portuguese (pt)
Inventor
Falkner Falko-Guenter
Erlich Hartmut
Barrett Noel
Kistner Otfried
Original Assignee
Baxter Int Inc E Baxter Healthcare S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int Inc E Baxter Healthcare S A filed Critical Baxter Int Inc E Baxter Healthcare S A
Publication of BRPI0923448A2 publication Critical patent/BRPI0923448A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0923448A 2008-12-16 2009-12-16 vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina. BRPI0923448A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12296108P 2008-12-16 2008-12-16
PCT/US2009/068321 WO2010077986A2 (en) 2008-12-16 2009-12-16 Production of viral vaccine

Publications (1)

Publication Number Publication Date
BRPI0923448A2 true BRPI0923448A2 (pt) 2018-10-09

Family

ID=41666658

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923448A BRPI0923448A2 (pt) 2008-12-16 2009-12-16 vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.

Country Status (10)

Country Link
US (1) US9884105B2 (https=)
EP (1) EP2376628B1 (https=)
JP (1) JP5686741B2 (https=)
KR (1) KR20110113615A (https=)
CN (2) CN107365751B (https=)
AU (2) AU2009333208A1 (https=)
BR (1) BRPI0923448A2 (https=)
ES (1) ES2675771T3 (https=)
SG (1) SG172220A1 (https=)
WO (1) WO2010077986A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2563389B1 (en) * 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
KR101250005B1 (ko) 2010-12-31 2013-04-03 연세대학교 산학협력단 바이러스 유전자 조작을 통한 생백신 제조방법
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
KR20150110494A (ko) * 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
SG11201507454XA (en) 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
CN104073513B (zh) * 2013-03-25 2018-04-20 中国科学院上海巴斯德研究所 甲型流感病毒疫苗哺乳动物细胞适应株的获得方法和适应位点
SG11201509265SA (en) * 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
CN105483149A (zh) * 2015-12-25 2016-04-13 吉林农业大学 广谱型抗禽流感重组乳酸菌及其制备方法
CN105950789A (zh) * 2016-07-14 2016-09-21 广西壮族自治区兽医研究所 一种鉴定h5亚型aiv、n6亚型aiv和aiv的引物组合及其应用
KR101966346B1 (ko) * 2017-01-13 2019-04-05 전북대학교 산학협력단 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물
WO2019044636A1 (ja) 2017-08-28 2019-03-07 一般財団法人阪大微生物病研究会 リアソータントインフルエンザウイルスの段階的作出方法
KR102182987B1 (ko) * 2018-06-27 2020-11-27 대한민국 재조합 인플루엔자 a 바이러스 h5n1주 및 이를 포함하는 고병원성 인플루엔자 a 바이러스 백신 조성물
CN109096377B (zh) * 2018-09-19 2021-03-23 天康生物股份有限公司 禽流感病毒血凝素抗原及表达其的bhk-21细胞株、制备方法和疫苗
CN109134624A (zh) * 2018-09-19 2019-01-04 天康生物股份有限公司 禽流感病毒血凝素抗原及其制备方法、应用和禽流感疫苗
KR102182999B1 (ko) * 2019-01-04 2020-11-25 대한민국 재조합 인플루엔자 A 바이러스 및 이를 포함하는 clade 2.3.4.4B에 속하는 H5 혈청형 인플루엔자 A 바이러스에 대한 백신 조성물
KR102182997B1 (ko) * 2019-01-04 2020-11-26 대한민국 H5N6형 재조합 인플루엔자 A 바이러스 및 이를 포함하는 clade 2.3.4.4D에 속하는 H5 혈청형 인플루엔자 A 바이러스에 대한 백신 조성물
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN111647610B (zh) * 2020-06-02 2021-09-03 扬州大学 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用
WO2021257469A1 (en) * 2020-06-15 2021-12-23 Icahn School Of Medicine At Mount Sinai Immunoassay for the detection of anti-sars-cov-2 spike protein antibody in milk samples
CN114524862B (zh) * 2021-12-16 2022-12-27 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 禽流感(h5+h7)三价dna疫苗的构建及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552758A (en) 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US6022726A (en) 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
DE69937999T2 (de) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6803041B2 (en) 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CN1618956A (zh) * 2003-11-20 2005-05-25 中国科学院武汉病毒研究所 一种禽流感预防用病毒株及其动物感染模型
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
HUE025727T2 (en) 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
JP4980895B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
DK2497492T3 (en) 2004-06-01 2018-11-26 Icahn School Med Mount Sinai Genetically modified swine influenza virus and its applications
EP2769735B1 (en) 2004-10-06 2017-04-19 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
EP1945778B1 (en) 2005-10-17 2012-12-26 MedImmune, LLC Methods of increasing influenza virus replication
US20080014217A1 (en) 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CN104140958A (zh) 2006-08-09 2014-11-12 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
CA2666980A1 (en) 2006-09-26 2008-04-03 Id Biomedical Corporation Of Quebec Device and methods of inactivating influenza virus and adventitious agents with ultraviolet light
JP2010512748A (ja) 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
EP2674486A1 (en) 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide

Also Published As

Publication number Publication date
AU2009333208A1 (en) 2010-07-08
EP2376628B1 (en) 2018-05-16
CN102257135A (zh) 2011-11-23
AU2016201038A1 (en) 2016-03-10
WO2010077986A2 (en) 2010-07-08
JP5686741B2 (ja) 2015-03-18
EP2376628A2 (en) 2011-10-19
CN107365751B (zh) 2021-07-09
CN107365751A (zh) 2017-11-21
CN102257135B (zh) 2017-06-09
SG172220A1 (en) 2011-07-28
ES2675771T3 (es) 2018-07-12
US20100189745A1 (en) 2010-07-29
KR20110113615A (ko) 2011-10-17
WO2010077986A3 (en) 2010-10-07
US9884105B2 (en) 2018-02-06
JP2012511914A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
BRPI0923448A2 (pt) vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.
CL2014002415A1 (es) Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11).
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
BR112012019757A2 (pt) composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular
BR112018008078A2 (pt) vacina de vírus influenza de amplo espectro
BRPI1007721A2 (pt) composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo
BRPI0905725A2 (pt) vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
MX2014010417A (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
BR112013030321A2 (pt) composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv.
MX2022002106A (es) Formulaciones de vacuna de vial unico.
CR20140189S (es) Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
BR112014010545A2 (pt) composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112014001049A2 (pt) método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
UY36395A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
MX363464B (es) Vacunas contra influenza h5.
CL2015001803A1 (es) Composición inmunogénica que comprende cepas del virus del oeste del nilo muerto o inactivado o cualquier antígeno del mismo; y método para disminuir síntomas clínicos asociados a infección por dicho virus en animales (div. sol. n° 445-11)

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.